Patents

US 12070453 B2: Treatment of Fabry disease in ERT-naïve and ERT-experienced patients

Granted
2024-08-27
Filed
2017-07-19 application 16318905
Type
Utility · 17 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-nave Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.

Source: PVGPATDIS, file of 2026-04-10 (ipg240827.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Amicus Therapeutics, Inc. 158 patentsUS company or organizationPhiladelphia, PAAMICUS THERAPEUTICS, INC. Form D issuer EXACT high confidence: identical full name and state
AMICUS THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Jeff CastelliNew Hope, PA59PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K31/445PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P3/00PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2026-04-27Release of security interest
Release of security interest
WILMINGTON TRUST, NATIONAL ASSOCIATION signed 2026-04-27AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA75494/30PASDL, file of 2026-08-13
2026-04-27Security interest Security interest
Security interest
BIOMARIN PHARMACEUTICAL INC. signed 2026-04-27
AMICUS THERAPEUTICS, INC. signed 2026-04-27
CITIBANK, N.A., AS COLLATERAL AGENT NEW YORK, NY75493/968PASDL, file of 2026-10-15
2024-07-11Assignment
Assignment of assignor's interest
CASTELLI, JEFF signed 2024-07-11AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA67959/418PASDL, file of 2026-10-15
2023-10-06Security interest Security interest
Security interest
AMICUS THERAPEUTICS, INC. signed 2023-10-05WILMINGTON TRUST, NATIONAL ASSOCIATION MINNEAPOLIS, MN65177/196PASDL, file of 2026-10-15
2023-10-06Release of security interest
Release of security interest
HAYFIN SERVICES LLP signed 2023-10-05AMICUS THERAPEUTICS, INC. PRINCETON, NJ65164/945PASDL, file of 2026-10-15
2020-07-30Security interest Security interest
Security interest
AMICUS THERAPEUTICS, INC. signed 2020-07-30HAYFIN SERVICES LLP, AS AGENT LONDON53365/342PASDL, file of 2026-10-15
2020-07-30Release of security interest
Release of security interest
BPCR LIMITED PARTNERSHIP signed 2020-07-30AMICUS THERAPEUTICS, INC. CRANBURY, NJ53360/659PASDL, file of 2026-10-15
2020-05-21Assignment
Omnibus confirmation of assignment agreement
BIOPHARMA CREDIT PLC signed 2020-05-21BPCR LIMITED PARTNERSHIP EXETER EX4 4EP52741/173PASDL, file of 2026-10-15
2020-05-11Security interest Security interest
Security interest
AMICUS THERAPEUTICS, INC. signed 2020-05-07BIOPHARMA CREDIT PLC EXETER EX4 4EP52625/916PASDL, file of 2026-10-15

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.